MacroGenics to Participate in Upcoming Investor Conference
MacroGenics (NASDAQ: MGNX), a biopharmaceutical company specializing in antibody-based cancer therapeutics, has announced its participation in the upcoming Citizens Life Sciences Conference in New York. The company's management team will engage in a fireside chat on May 8, 2025, at 10:30am ET, along with one-on-one meetings.
A webcast of the presentation will be available in the Investor Relations section of MacroGenics' website and will remain accessible for 30 days after the event.
MacroGenics (NASDAQ: MGNX), un'azienda biofarmaceutica specializzata in terapie oncologiche basate su anticorpi, ha annunciato la sua partecipazione alla prossima Citizens Life Sciences Conference a New York. Il team di gestione dell'azienda parteciperà a una conversazione informale il 8 maggio 2025 alle 10:30 ET, oltre a incontri individuali.
Una trasmissione in diretta della presentazione sarà disponibile nella sezione Investor Relations del sito web di MacroGenics e resterà accessibile per 30 giorni dopo l'evento.
MacroGenics (NASDAQ: MGNX), una empresa biofarmacéutica especializada en terapias oncológicas basadas en anticuerpos, ha anunciado su participación en la próxima Citizens Life Sciences Conference en Nueva York. El equipo directivo de la compañía participará en una charla informal el 8 de mayo de 2025 a las 10:30 am ET, además de reuniones individuales.
Una transmisión en línea de la presentación estará disponible en la sección de Relaciones con Inversores del sitio web de MacroGenics y permanecerá accesible durante 30 días después del evento.
MacroGenics (NASDAQ: MGNX)는 항체 기반 암 치료제를 전문으로 하는 바이오제약 회사로, 뉴욕에서 열리는 Citizens Life Sciences Conference에 참여할 것이라고 발표했습니다. 회사 경영진은 2025년 5월 8일 오전 10시 30분 ET에 진행되는 대화식 토론에 참여하며, 1:1 미팅도 진행할 예정입니다.
발표 웹캐스트는 MacroGenics 웹사이트의 투자자 관계 섹션에서 제공되며, 행사 후 30일 동안 시청할 수 있습니다.
MacroGenics (NASDAQ : MGNX), une société biopharmaceutique spécialisée dans les thérapies anticorps contre le cancer, a annoncé sa participation à la prochaine Citizens Life Sciences Conference à New York. L'équipe de direction de l'entreprise participera à une discussion informelle le 8 mai 2025 à 10h30 ET, ainsi qu'à des réunions individuelles.
Une retransmission en direct de la présentation sera disponible dans la section Relations Investisseurs du site web de MacroGenics et restera accessible pendant 30 jours après l'événement.
MacroGenics (NASDAQ: MGNX), ein biopharmazeutisches Unternehmen, das sich auf antikörperbasierte Krebstherapeutika spezialisiert hat, hat seine Teilnahme an der bevorstehenden Citizens Life Sciences Conference in New York angekündigt. Das Management-Team des Unternehmens wird sich am 8. Mai 2025 um 10:30 Uhr ET an einem Gespräch am Kamin beteiligen und Einzelgespräche führen.
Ein Webcast der Präsentation wird im Bereich Investor Relations auf der Website von MacroGenics verfügbar sein und ist 30 Tage nach der Veranstaltung abrufbar.
- None.
- None.
ROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company's management team will participate in the following investor conference this month:
- The Citizens Life Sciences Conference (New York). Members of MacroGenics’ management team will participate in a fireside chat on Thursday, May 8, 2025, at 10:30am ET. Management will also participate in one-on-one meetings.
A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of the webcast on its website for 30 days.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and DART are trademarks or registered trademarks of
MacroGenics, Inc.
Contacts: Jim Karrels, Senior Vice President, CFO 1-301-251-5172 info@macrogenics.com Argot Partners 1-212-600-1902 macrogenics@argotpartners.com
FAQ
When is MacroGenics (MGNX) presenting at the Citizens Life Sciences Conference 2025?
Where can I watch MacroGenics' (MGNX) presentation at the Citizens Life Sciences Conference?
What type of meetings will MacroGenics (MGNX) management participate in at the Citizens Life Sciences Conference?
What is MacroGenics' (MGNX) main business focus?
